Who are dapsone gel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aczone, Aldapsone, Aczone 5% gel, Dapsone plus Adapalene, Dapsone 7.5 % gel, Dapsone gel, 5%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dapsone-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

dapsone gel — Competitive Intelligence Brief

dapsone gel (dapsone gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfone [EPC].

marketed Sulfone [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

dapsone gel (dapsone gel) — Almirall, S.A..

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
dapsone gel TARGET	dapsone gel	Almirall, S.A.	marketed	Sulfone [EPC]
Aczone	DAPSONE	Almirall	marketed	Sulfone [EPC]	5-hydroxytryptamine receptor 6	1979-01-01
Aldapsone	aldesulfone	AbbVie	marketed	aldesulfone	Glucose-6-phosphate 1-dehydrogenase, Dihydropteroate synthase 1	1974-01-01
Aczone 5% gel	Aczone 5% gel	Derm Research, PLLC	marketed	Sulfone antimicrobial agent	Bacterial dihydropteroate synthase; anti-inflammatory mechanisms
Dapsone plus Adapalene	Dapsone plus Adapalene	Allergan	marketed	Retinoid plus sulfone antibiotic combination	Retinoic acid receptors (adapalene); dihydrofolate reductase inhibition and neutrophil suppression (dapsone)
Dapsone 7.5 % gel	Dapsone 7.5 % gel	Derm Research, PLLC	marketed	Sulfone antibiotic with anti-inflammatory properties	Dihydropteroate synthase; neutrophil function and inflammatory mediators
Dapsone gel, 5%	Dapsone gel, 5%	Vanderbilt University Medical Center	marketed	Sulfone antimicrobial and anti-inflammatory agent	Dihydrofolate reductase; neutrophil function modulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfone [EPC] class)

Almirall · 1 drug in this class
Almirall, S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). dapsone gel — Competitive Intelligence Brief. https://druglandscape.com/ci/dapsone-gel. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab